The Canadian R&D company Entheon Biomedical has set out to investigate the therapeutic use of the psychedelic dimethyltryptamine (DMT) in treating addiction disorders. Specifically, the company has commissioned a clinical trial investigating the safety and efficacy of using intravenous DMT.
Silo Pharma Inc. Discusses The Potential of Merging Traditional Therapeutics with Psychedelic Research On The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - January 20, 2021) - The Stock Day Podcast welcomed Silo Pharma Inc. (OTCQB: SILO) ("the Company"), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson's, and other rare neurological disorders. CEO of the Company, Eric Weisblum, joined Stock Day host Everett Jolly.
Top Penny Stocks To Watch For 2021 If You’re Following Mushroom Stocks
Whether you’ve traded for decades or just opened an account, the market attracts you for a reason.
Entheon Biomedical Partners with Divergence Neuro Technologies Inc. for Predictive Biomarker Platform Development
Entheon announces a new partnership to advance its psychedelic drug R&D.
Low Tide For Psychedelic Stocks With Media, Investors Distracted
The U.S. election has become a major political circus. With investors distracted and the media focused elsewhere, psychedelic stocks are temporarily at low tide.
Psychedelic Schools for ‘Shamans’ Are Popping Up Like Mushrooms
Even before Oregon and Washington, D.C., decriminalized medical psilocybin, the active ingredient in “magic mushrooms,” in November, a market was emerging for schools that teach mental and medical health professionals how to use psychedelics in their treatment.
The public’s perception of the harms of magic mushrooms is in line with science — but not with the law
New research suggests that the public’s perception of the potential harms of magic mushrooms is not in line with drug laws.
Cybin Announces CDN$20 Million Bought Deal Offering
Cybin Corp announces a CAD$20 million financing at a unit price of CAD$2.25.
What Will The Psychedelics Space Look Like In 2021? Experts Weigh In
In 2020, psychedelics took the world by storm. Over two dozen companies in the sector became publicly listed.
Local Massachusetts Lawmakers Unanimously Approve Psychedelics Decriminalization Measure
Local Massachusetts lawmakers on Thursday unanimously approved a resolution to decriminalize a wide range of psychedelics—the latest in a national movement to reform laws on entheogenic plants and fungi.
Peter Thiel-backed psychedelics start-up targets schizophrenia ahead of IPO
LONDON — ATAI Life Science, a Peter Thiel-backed start-up, has taken a majority stake in Recognify, a company that is developing drugs to help treat schizophrenia.
Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units
Mydecine announces a bought-deal financing with units priced at CAD$0.50.
